Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00291005 | PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone | PHASE2 | COMPLETED | 42 | — | — | Aug 1, 2004 | - | Mar 27, 2009 | 1 | Japan |
| Name | Type | Description |
|---|---|---|
| ARD6562, Docetaxel | DRUG | - |
Inclusion Criteria: * Men with prostate adenocarcinoma with at least one metastatic lesion which is measurable and who progressed after prior hormonal therapy. Exclusion Criteria: * 1.Body temperature \> 38 degree centigrade. * 2.Prior radiotherapy to \> 25% of bone marrow. * 3.Prior isotope ther...